Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue EBIAT Gross Profit Leases Long-Term Debt Issuances Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Preferred Shares Issued Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Shares Issued Shares Outstanding Shares Outstanding

TriSalus Life Sciences (TLSI) Long-Term Debt Issuances (2022 - 2025)

TriSalus Life Sciences has reported Long-Term Debt Issuances over the past 4 years, most recently at $10.0 million for Q1 2025.

For Q1 2025, Long-Term Debt Issuances changed N/A year-over-year to $10.0 million; the TTM value through Dec 2025 reached $10.0 million, down 60.0%, while the annual FY2025 figure was $10.0 million, 60.0% down from the prior year.
Long-Term Debt Issuances for Q1 2025 was $10.0 million at TriSalus Life Sciences, down from $25.0 million in the prior quarter.
Over five years, Long-Term Debt Issuances peaked at $25.0 million in Q2 2024 and troughed at -$415222.0 in Q2 2023.
A 4-year average of $5.9 million and a median of $340111.0 in 2022 define the central range for Long-Term Debt Issuances.
Biggest five-year swings in Long-Term Debt Issuances: tumbled 407.57% in 2023 and later skyrocketed 6120.88% in 2024.
Year by year, Long-Term Debt Issuances stood at $135000.0 in 2022, then tumbled by 407.57% to -$415222.0 in 2023, then skyrocketed by 6120.88% to $25.0 million in 2024, then tumbled by 60.0% to $10.0 million in 2025.
Business Quant data shows Long-Term Debt Issuances for TLSI at $10.0 million in Q1 2025, $25.0 million in Q2 2024, and -$415222.0 in Q2 2023.